18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.
Stanley D Glick, Isabelle M Maisonneuve, K E Visker, K A Fritz, Upul K. Bandarage, Martin E. Kuehne
Psychopharmacology October 1, 1998 DOI: 10.1007/s002130050716 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Awake and freely moving rats |
| Interventions | Ibogaine 18-methoxycoronaridine (18-MC) |
| Dose | 40 mg/kg, i.p. |
| Duration | At least 24 hours |
| Keywords | Nicotine addiction treatment Smoking cessation Quit smoking Tobacco dependence treatment Anti-smoking therapy Treatments Drug discovery Pharmaceutical research New drug development Therapeutic compounds 18-methoxycoronardine 18-mc Neuropharmacology Brain research Dopamine system Dopamine surge Preclinical research Animal studies Rat experiments In vivo research Rats |
| Citations | 45 |
| Key points | 18-MC attenuated nicotine-induced dopamine release in the nucleus accumbens and selectively reduced nicotine self-administration in rats without affecting water intake. |
Abstract
Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/kg, i.p.) significantly attenuated nicotine-induced dopamine release in the nucleus accumbens of awake and freely moving rats. In an oral model of nicotine self-administration, both ibogaine and 18-MC decreased rats' preferences for nicotine for at least 24 h. Acutely, during the first hour after administration, ibogaine depressed responding for water as well as for nicotine; however, during this same time, 18-MC reduced nicotine intake without affecting responding for water. The results suggest that 18-MC might be the prototype of a new treatment for smoking.
Citations in the library
Cited by 17
- Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology August 1, 2016
- The ibogaine medical subculture. Journal of Ethnopharmacology January 4, 2008
- Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse 2018
- Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacology, Biochemistry, and Behavior June 1, 2003
- Ibogaine in the treatment of substance dependence. Current Drug Abuse Reviews March 1, 2013
and 12 more in the library
Cites 13
- Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Research February 7, 1992
- Attenuation of alcohol intake by ibogaine in three strains of alcohol-preferring rats. Pharmacology, Biochemistry, and Behavior November 1, 1995
- Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. European Journal of Pharmacology June 18, 1991
- 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Research May 6, 1996
- Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology April 1, 1995
and 8 more in the library